Sanofi (Sanofi) Deferred Tax

: $-184 Mil (TTM As of Jun. 2023)

View and export this data going back to 2002. Start your Free Trial

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Sanofi's change in deferred tax for the six months ended in Jun. 2023 was $0 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Jun. 2023 was $-184 Mil.

Sanofi Deferred Tax Historical Data

The historical data trend for Sanofi's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Deferred Tax

-1,968.89

-268.86

-402.26

-612.29

-1,057.80

Sanofi Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Deferred Tax																-	-427.06	-184.32	-	-

Sanofi Deferred Tax Calculation

Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-184 Mil.

Sanofi Deferred Tax Related Terms

Thank you for viewing the detailed overview of Sanofi's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi (Sanofi) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Deferred Tax

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:Mexico SANF:Italy 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SNW2:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SANO:Austria

Address

46, avenue de la Grande Armée, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.